Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Prilosec Risk/Benefit Ratio Relative To Current OTCs Questioned By Andrx

This article was originally published in The Tan Sheet

Executive Summary

Uncertainties about the safety and efficacy of OTC Prilosec (omeprazole 20 mg) combined with "the relative effectiveness" of currently available nonprescription acid-reducers, should cause FDA to deny Procter & Gamble/AstraZeneca's switch NDA, Andrx says in a Nov. 20 citizen petition

You may also be interested in...



Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions

A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change

Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions

A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change

Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions

A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS094858

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel